BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $100 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Credit Suisse analyst Martin Auster lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $100.00 (from $102.00) while maintaining a Outperform rating.
You May Also Be Interested In
- BioMarin Pharma (BMRN) Tops Q3 EPS by 11c
- Estee Lauder (EL) PT Raised to $129 at Goldman Sachs
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
